Skip to main content

Please wait ...

Phil Wolfson, MD


Phil Wolfson, MD, is the creator of a new psychotherapy modality based on use of the medicine ketamine – Ketamine Assisted Psychotherapy (KAP). Phil is the CEO of the non-profit Ketamine Research Foundation and directs the training of KAP practitioners through The Ketamine Training Center - now numbering over 1000 practitioners across the US and internationally. KRF’s Ketamine Psychotherapy Associates membership organization promotes the development of KAP practices and KAP wisdom on an ongoing basis. He is the author of The Ketamine Papers and Noe – A Father/Son Song of Love, Life, Illness and Death. He has been the principal investigator of the MAPS.org Phase 2 study of MDMA treatment for individuals with life-threatening illnesses. Dr. Wolfson’s work is the result of an intense, now many decades long clinical psychiatry/psychotherapy practice. He is a founder of Progressive Therapeutics Inc, an exciting new commercial psychedelic and psychoactive drug development corporation that is allied with his non-profit. The second volume of The Ketamine Papers is being prepared for publication in 2025.

He was featured in lead articles in the New Yorker, Vanity Fair and Oprah Magazine. KRF’s research, education and training are leading in the field.

Phil Wolfson is a sixties activist, psychiatrist/psychotherapist, writer, practicing Buddhist and psychonaut who has lived in the Bay Area for 46 years. In the 1980s, he participated in clinical research with MDMA (Ecstasy). He has created 9 patents for unique herbal medicines and ketamine. Phil was a founding member of the Heffter Research Institute. He is a journalist and author of numerous articles on politics, transformation, psychedelics, consciousness and spirit.

He is a graduate of Brandeis University and NYU School of Medicine.
 

Speaker Disclosures:
Financial: Philip Wolfson is the founder and CEO of The Ketamine Research Foundation. He has an ownership interest in Progressive Therapeutics, Inc. Dr. Wolfson will address off-label uses. He has no relevant financial relationships with ineligible organizations.
Non-financial: Philip Wolfson has no relevant non-financial relationship to disclose.

 

Products 1 through 5 out of 5

The Use of Mind-Altering Substances: MDMA, Psilocybin, and Marijuana for Treating PTSD and other Mental Distress


Faculty:
Michael Mithoefer, MD |  Rick Doblin, PhD |  Phil Wolfson, MD |  Sue Carter, PhD |  Robin Carhart-Harris, PhD |  Andrew Penn, RN, MS, NP, CNS, APRN-BC |  Richard C. Schwartz, PhD |  Anne Wagner, PhD, C Psych |  ....
Duration:
3 Hours 59 Minutes
Copyright:
18 May, 2021
Product Code:
POS052719
Media Type:
Digital Seminar
Price:
$91.95 - Anniversary Sale 2025 - 46% off Normal Price: Standard - $169.95

The Fantastic Effects of Ketamine Assisted Psychotherapy: A Revolution in Clinical Practice


Faculty:
Phil Wolfson, MD
Duration:
1 Hour
Format:
Audio and Video
Copyright:
28 Jul, 2022
Product Code:
NOS096253
Media Type:
Digital Seminar
Price:
$37.95 - Anniversary Sale 2025 - 46% off Normal Price: Standard - $69.95

Psychedelic-Assisted Psychotherapy for Trauma: Essential Insights into Ketamine, MDMA, Psilocybin, & More

Essential Insights into Ketamine, MDMA, Psilocybin, & More

Faculty:
Gabor Maté, MD |  Ronald D. Siegel, PsyD |  Bessel A. van der Kolk, MD |  Phil Wolfson, MD |  Richard C. Schwartz, PhD |  Janis Phelps, PhD |  Gita Vaid, MD
Duration:
18 Hours 8 Minutes
Copyright:
31 Aug, 2022
Product Code:
CRS001551
Media Type:
Online Course
Price:
$745.14 Normal Price: Standard - $1,379.90

Psychedelics in Therapy

MDMA, Psilocybin, Ketamine, Micro-Dosing, & More

Faculty:
Elizabeth Nielson, PhD |  Ingmar Gorman, PhD |  Seema Desai, MD |  Jeffrey Guss, MD |  Gabor Maté, MD |  Matthew W. Johnson, PhD |  Victor Cabral, MSW, LSW, CCTP-I |  Phil Wolfson, MD |  ....
Duration:
10 Hours 20 Minutes
Copyright:
25 Aug, 2023
Product Code:
NRS001612
Media Type:
Online Course
Price:
$377.95 Normal Price: Standard - $699.90

Pagination

Showing 1 to 5 of 5 entries